What is Sensorion?
Founded in 2009 and headquartered in Montpellier, France, Sensorion is dedicated to developing novel therapies aimed at restoring, treating, and preventing hearing loss. The company operates within the specialized field of audiology and otology, targeting a significant unmet medical need. Its clinical-stage status indicates a progression from early research to human trials, underscoring its commitment to bringing innovative treatments to market.
How much funding has Sensorion raised?
Sensorion has raised a total of $64.8M across 2 funding rounds:
Grant
$10.4M
Other Financing Round
$54.4M
Grant (2019): $10.4M with participation from Hospital Research-University
Other Financing Round (2024): $54.4M led by Redmile Group, Invus, and Sofinnova Partners
Key Investors in Sensorion
Redmile Group
Redmile Group LLC is a venture capital and private equity firm based in New York City, New York, likely focusing on investments within the life sciences sector.
Invus
Invus Group, established in 1985 and headquartered in New York City, is an investment firm providing financial advice, investment services, and consulting, with a potential interest in healthcare and biotechnology.
Sofinnova Partners
Sofinnova Partners is a prominent European venture capital firm specializing in Life Sciences, investing from early-stage to late-stage companies with a focus on paradigm-shifting technologies.
What's next for Sensorion?
The recent major strategic investment signals strong confidence from backers in Sensorion's technology and market potential. This financing is expected to accelerate the company's research and development efforts, potentially enabling the progression of its lead drug candidates through clinical trials and towards regulatory approval. The strategic nature of the funding suggests potential collaborations or synergistic opportunities that could further enhance Sensorion's growth trajectory and market positioning in the competitive biotech landscape.
See full Sensorion company page
